Cargando…
Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial
BACKGROUND: COVID-19 vaccines that offer broad-spectrum protection are needed. We aimed to evaluate the safety and immunogenicity of multivalent vaccines, SCTV01E and SCTV01C, and compare them with an inactivated vaccine. METHODS: In the phase 3 trial (ClinicalTrials.gov: NCT05323461), adult partici...
Autores principales: | Hannawi, Suad, Yan, Lixin, Saifeldin, Linda, Abuquta, Alaa, Alamadi, Ahmad, Mahmoud, Sally A., Hassan, Aala, Zhang, Miaomiao, Gao, Cuige, Chen, Yuanxin, Gai, Wenlin, Xie, Liangzhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507195/ https://www.ncbi.nlm.nih.gov/pubmed/37731938 http://dx.doi.org/10.1016/j.eclinm.2023.102195 |
Ejemplares similares
-
Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial
por: Hannawi, Suad, et al.
Publicado: (2022) -
Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial
por: Hannawi, Suad, et al.
Publicado: (2022) -
Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men
por: Hannawi, Suad, et al.
Publicado: (2023) -
Safety and immunogenicity of boosting with a severe acute respiratory syndrome coronavirus 2 omicron variant mRNA vaccine in healthy adults: An open‐label, and single‐arm Phase 1 study
por: Hannawi, Suad, et al.
Publicado: (2023) -
Comparative analysis of the immunogenicity of monovalent and multivalent rotavirus immunogens
por: Mi, Kai, et al.
Publicado: (2017)